The protoxin Cry1Ac of Bacillus thuringiensis improves the protection conferred by intranasal immunization with Brucella abortus RB51 in a mouse model |
| |
| Affiliation: | 1. Laboratorio de Inmunidad en Mucosas, Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Avenida de los Barrios 1, Los Reyes Iztacala, Tlalnepantla 54090, Estado de México, Mexico;2. Laboratorio de Inmunología Médica, Escuela Superior de Medicina, Instituto Politécnico Nacional, Unidad Profesional Lázaro Cárdenas, Avenida Salvador Díaz Mirón s/n esquina Plan de San Luis, Col. Santo Tomás, Delegación Miguel Hidalgo 11340, Distrito Federal, Mexico;3. Laboratorio de Inmunología Celular Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Unidad Profesional Lázaro Cárdenas, Prolongación de Carpio y Plan de Ayala s/n, Col. Santo Tomás, Delegación Miguel Hidalgo 11340, Distrito Federal, Mexico;1. Institute of Microbiology and Immunology, University of Belgrade Faculty of Medicine, Belgrade, Serbia;2. Institute for Infectious and Tropical Diseases CCS, HIV/AIDS Unit, Belgrade, Serbia;1. Institut für Tropenmedizin, Eberhard Karls Universität Tübingen, Deutsches Zentrum für Infektionsforschung, Tübingen, Germany;2. Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon;3. Institute of Hygiene, University Hospital Münster, Münster, Germany;4. Institute of Medical Microbiology, University Hospital Münster, Münster, Germany;1. Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA;2. Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA;1. Sección de Neurobiología de las Sensaciones Orales, Laboratorio de Investigación Odontológica, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México Sección de Neurobiología de las sensaciones orales, Facultad de Estudios Superiores Iztacala, UNAM, Av. de los Barrios 1, Los reyes Ixtacala, Hab Los Reyes Ixtacala Barrio de los Árboles/Barrio de los Héroes, 54090 Tlalnepantla, Mexico;2. Laboratorio de Neurofarmacología Conductual, Unidad Interdisciplinaria en ciencias de la Salud y la Eduación. Facultad de Estudios Superiores Iztacala, UNAM, Av De Los Barrios 1, Los Reyes Ixtacala, Hab Los Reyes Ixtacala Barrio de los Árboles/Barrio de los Héroes, 54090 Tlalnepantla, Mexico;1. Fundamental and Applied Research for Animals & Health (FARAH), Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium;2. Parasitology and Parasitic Diseases Unit, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Cluj-Napoca, Romania;3. Laboratory of Venin and Biological Activities, Jean-Francois Champollion University Center, Albi, France;4. FARAH, Department of Morphology and Pathology, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium |
| |
| Abstract: | Brucellosis is a zoonotic disease affecting many people and animals worldwide. Preventing this infection requires improving vaccination strategies. The protoxin Cry1Ac of Bacillus thuringiensis is an adjuvant that, in addition to increasing the immunogenicity of different antigens, has shown to be protective in different models of parasitic infections. The objective of the present study was to test whether the intranasal co-administration of pCry1Ac with the RB51 vaccine strain of Brucella abortus confers protection against an intranasal challenge with the virulent strain B. abortus 2308 in BALB/c mice. The results showed that co-administration of pCry1Ac and RB51, increased the immunoprotection conferred by the vaccine as evidenced by the following: (1) decrease of the splenic bacterial load when challenged intranasally with the virulent strain; (2) greater in vivo cytotoxic activity in response to the transference of previously infected cells; (3) further proliferation of cytotoxic TCD8+ cells in response to stimulation with heat-inactivated bacteria; (4) increased production of TNF-α and IFN-γ; and (5) significant IgG2a response. These results indicate that the use of the Cry1Ac protein as a mucosal adjuvant via the intranasal route can be a promising alternative for improving current RB51 vaccine against brucellosis. |
| |
| Keywords: | Brucellosis Adjuvants Intranasal vaccine Cry1Ac protoxin RB51 vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
